PMC:6723065 / 73142-73762 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/6723065","sourcedb":"PMC","sourceid":"6723065","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6723065","text":"NCT00660387/LCIG Levodopa-Carbidopa intestinal gel (LCIG), administered by continuous intra-intestinal infusion (Duodopa®) - Change from baseline to week 12 in average daily normalized off-time- Change from baseline in average daily normalized on-time without troublesome dyskinesia at week 12 Reduced OFF-time after 12 weeks by 4 h compared to baseline and 1.91 h compared to standard oral formulation.Reduced OFF time by 4.04 h in LDIG group vs. 2.14 h in the standard oral formulation group (p = 0.0015)Increase in on-time without troublesome dyskinesia (TSD) Approved by FDA/EUNo difference in UPDRS motor scores","divisions":[{"label":"td","span":{"begin":0,"end":17}},{"label":"td","span":{"begin":18,"end":123}},{"label":"td","span":{"begin":125,"end":295}},{"label":"td","span":{"begin":297,"end":565}}],"tracks":[]}